



BSE: 500257	NSE: LUPIN	REUTERS: LUPIN.BO	BLOOMBERG: LPC IN
-------------	------------	-------------------	-------------------

## **Lupin Announces Licensing Arrangement with NeuClone Inks strategic deal with NeuClone for Cell line Technology**

Mumbai / Sydney, 1 June, 2011: Pharma Major, Lupin Limited, today announced a strategic licensing agreement with Sydney based private specialty life science company NeuClone Pty Ltd for their cell line technology.

Under the terms of the agreement, NeuClone will provide an exclusive proprietary mammalian CHO cell line which will express a specific recombinant protein of interest in Oncology to its partner. The agreement will also entail the Lupin Biological Research Program scientific research staff working with NeuClone Teams at their facility as a part of the overall technology transfer arrangements as specified within the agreement.

Commenting on the agreement Dr. Cyrus Karkaria, President, Lupin Limited and Head of the Lupin Biological Research Program said "The multi-billion dollar opportunity with blockbuster Biologics going off patent in the next 5-8 years is something that Lupin is pursuing aggressively. This exclusive licensing arrangement with NeuClone is a part of that strategy and would enable us to capitalize on cutting edge technology to address the Biologicals Market. This agreement and such similar agreements, coupled with our own pipeline will go a long way in helping us address the impending opportunity and develop a substantial differentiated biological pipeline."

NeuClone CEO, Dr Noelle Sunstrom said "This is an exciting time for NeuClone and our stakeholders as our investment in mammalian CHO cell lines is commercialised. In particular, we are enthusiastic about further developing the relationship with Lupin, an important global generic manufacturer."

### **About Lupin**

Headquartered in Mumbai, India, Lupin Limited is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs. The Company today has significant presence in Cardiovasculars (prils and statins), Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infectives and NSAIDs in addition to holding global leadership positions in the Anti-TB and Cephalosporins space.

Today, Lupin is the 5<sup>th</sup> largest and the fastest growing Top 5 generics player in the U.S. (by prescriptions), the only Asian company to achieve that distinction. The company is also the fastest growing top 10 pharmaceutical players in India, Japan and South Africa. (IMS)

For the financial year ended March 2011, Lupin's Consolidated Sales and Profit after Tax were Rs. 57,068 million and Rs. 8,626 million respectively.

### **About NeuClone**

NeuClone is an Australian biotech company specializing in cell line engineering for the biopharmaceutical and biomanufacturing industries. NeuClone has developed technology in recombinant protein production. NeuClone's expression platform is designed for safe, robust and stable expression of therapeutic proteins and to reduce COGS in bio-manufacturing.

### **For further information on Lupin, please contact -**

Shamsher Gorawara  
Head - Corporate Communications  
Lupin Limited:  
Ph: +91 98 20 338 555  
Email: [shamshergorawara@lupinpharma.com](mailto:shamshergorawara@lupinpharma.com)

or

### **For further information on NeuClone, please contact -**

Dr Noelle Sunstrom,  
CEO, NeuClone Pty Ltd  
Ph: +612 9209 4020  
Email : [info@neuclone.com](mailto:info@neuclone.com)